NEW YORK MEDICAL COLLEGE

Agent

Name	Role
Registered Agent Revoked	Agent

DOS Process Agent

Name	Role	Address
THE CORPORATION	DOS Process Agent	ADMINISTRATION BUILDING, SUNSHINE COTTAGE, VALHALLA, NY, United States, 10595

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:

WK63UJ11C2H7

CAGE Code:

4B851

UEI Expiration Date:

2026-05-28

Business Information

URL:

http://www.nymc.edu

Activation Date:

2025-05-30

Initial Registration Date:

2001-11-14

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:

4B851

Status:

Active

Type:

Non-Manufacturer

CAGE Update Date:

2025-05-30

CAGE Expiration:

2030-05-30

SAM Expiration:

2026-05-28

Contact Information

POC:

SALOMON AMAR

Corporate URL:

http://www.nymc.edu

Immediate Level Owner

Vendor Certified:

2025-05-30

CAGE number:

3PFB8

Company Name:

TOURO COLLEGE

National Provider Identifier

NPI Number:

1164624748

Link:

View on NPI website

Authorized Person:

Name:

PROF. MICHAEL SOLOMON GOLIGORSKY

Role:

PROFESSOR, DIRECTOR, RENAL RES INST

Phone:

9145944730

Taxonomy:

Selected Taxonomy:

1744R1102X - Research Study Specialist

Is Primary:

Yes

Contacts:

Phone:

+1 914-594-4730

Fax:

9145944732

Form 5500 Series

Employer Identification Number (EIN):

131099420

Plan Year:

2015

Number Of Participants:

667

Sponsors Telephone Number:

9145944560

File:

View File

Plan Year:

2015

Number Of Participants:

883

Sponsors Telephone Number:

9145944560

File:

View File

Plan Year:

2014

Number Of Participants:

721

Sponsors Telephone Number:

9145944560

File:

View File

Plan Year:

2014

Number Of Participants:

958

Sponsors Telephone Number:

9145944560

File:

View File

Plan Year:

2013

Number Of Participants:

732

Sponsors Telephone Number:

9145944560

File:

View File

History

Start date	End date	Type	Value
2002-02-28	2024-05-29	Address	ADMINISTRATION BUILDING, SUNSHINE COTTAGE, VALHALLA, NY, 10595, USA (Type of address: Service of Process)
1983-02-28	2002-02-28	Address	ELMWOOD HALL, VALHALLA, NY, 10595, USA (Type of address: Service of Process)
1981-01-29	1983-02-28	Address	NEW YORK MEDICAL COLLEGE, ELMWOOD HALL, VALHALLA, NY, 10595, USA (Type of address: Service of Process)
1973-08-21	2024-05-29	Address	FIFTH AVE. AT 106TH ST., NEW YORK, NY, 10029, USA (Type of address: Registered Agent)
1970-11-17	1981-01-29	Address	106TH ST. & 5TH AVE., NEW YORK, NY, 10029, USA (Type of address: Service of Process)

Filings

Filing Number	Date Filed	Type	Effective Date
240529003608	2024-05-17	CERTIFICATE OF CHANGE BY ENTITY	2024-05-17
20150407027	2015-04-07	ASSUMED NAME CORP DISCONTINUANCE	2015-04-07
20150226076	2015-02-26	ASSUMED NAME CORP INITIAL FILING	2015-02-26
020228000775	2002-02-28	CERTIFICATE OF AMENDMENT	2002-02-28
A954415-10	1983-02-28	CERTIFICATE OF AMENDMENT	1983-02-28

USAspending Awards / Contracts

Procurement Instrument Identifier:

N0622A25F0098

Link:

View Award on USAspending website

Award Or Idv Flag:

AWARD

Award Type:

DELIVERY ORDER

Action Obligation:

102668.00

Base And Exercised Options Value:

102668.00

Base And All Options Value:

102668.00

Awarding Agency Name:

Department of Defense

Performance Start Date:

2024-11-06

Description:

TUITION AND FEES

Naics Code:

923110: ADMINISTRATION OF EDUCATION PROGRAMS

Product Or Service Code:

U005: EDUCATION/TRAINING- TUITION/REGISTRATION/MEMBERSHIP FEES

Procurement Instrument Identifier:

N0622A24F00KN

Link:

View Award on USAspending website

Award Or Idv Flag:

AWARD

Award Type:

DELIVERY ORDER

Action Obligation:

102680.00

Base And Exercised Options Value:

102680.00

Base And All Options Value:

102680.00

Awarding Agency Name:

Department of Defense

Performance Start Date:

2024-05-10

Description:

TUITION AND FEES

Naics Code:

923110: ADMINISTRATION OF EDUCATION PROGRAMS

Product Or Service Code:

U005: EDUCATION/TRAINING- TUITION/REGISTRATION/MEMBERSHIP FEES

Procurement Instrument Identifier:

N0622A24F00K2

Link:

View Award on USAspending website

Award Or Idv Flag:

AWARD

Award Type:

DELIVERY ORDER

Action Obligation:

-7543.00

Base And Exercised Options Value:

-7543.00

Base And All Options Value:

-7543.00

Awarding Agency Name:

Department of Defense

Performance Start Date:

2024-01-02

Description:

TUITION AND FEES

Naics Code:

923110: ADMINISTRATION OF EDUCATION PROGRAMS

Product Or Service Code:

U005: EDUCATION/TRAINING- TUITION/REGISTRATION/MEMBERSHIP FEES

USAspending Awards / Financial Assistance

Date:

2025-04-03

Link:

View on USAspending

Awarding Agency Name:

Department of Defense

Transaction Description:

IDENTIFICATION AND CIRCUMVENTION OF RESISTANCE AFTER DONOR-DERIVED EX VIVO EXPANDED NK CELLS AND HAPLO-HCT IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK AML. 1. REMOVE THE INCLUSION ENROLLEMENT REPORTING REQUIREMENT FROM ANNUAL AND FINAL TECHNICAL REPORTS CLAUSE IN THE TERMS AND CONDITIONS. 2. UPDATES DIVISION I ITEMS A.4 AND II

Obligated Amount:

1599743.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Date:

2025-05-12

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

TARGETING EBV'S DEUBIQUITINATING ACTIVITY FOR THERAPY - PROJECT SUMMARY/ABSTRACT EPSTEIN-BARR VIRUS (EBV), A HUMAN TUMOR VIRUS, IS THE CAUSATIVE AGENT OF MONONUCLEOSIS AND IMMUNOBLASTIC LYMPHOMAS. EBV IS STRONGLY ASSOCIATED WITH BURKITT’S LYMPHOMA, HODGKIN’S LYMPHOMA, AND NASOPHARYNGEAL CARCINOMA (NPC). ADDITIONALLY, RECENT STUDIES SUGGEST THAT EBV HAS A PATHOGENIC ROLE WITH THE ONSET OF MULTIPLE SCLEROSIS (MS). APPROXIMATELY 90% OF THE WORLD’S POPULATION IS INFECTED WITH EBV, BUT MOST DO NOT PRESENT DISEASE. HOWEVER, FOR THOSE THAT DO DEVELOP EBV-RELATED ILLNESS THERE REMAINS NO DIRECTED SMALL MOLECULE THERAPY. EBV-TRIGGERED DISEASE, CAUSING DEBILITATING ILLNESS AND DEATH, REMAINS A WORLD-WIDE PROBLEM. INTERESTINGLY, EBV EXPRESSES A UNIQUE PROTEIN (BPLF1) THAT POSSESSES DEUBIQUITINATING ACTIVITY. BPFL1 IS KNOWN TO REGULATE BOTH CELLULAR AND VIRAL TARGET ACTIVITIES, YET IT REMAINS LARGELY UNSTUDIED. OUR WORK HAS IMPLICATED BPLF1 IN A WIDE RANGE OF VIRAL AND CELLULAR PROCESSES INCLUDING INFECTIVITY (90% REDUCTION WITH KNOCKOUT OF BPLF1), VIRAL DNA REPLICATION, AND DNA REPAIR. ALSO WE RECENTLY REPORTED SURPRISING NEW FINDINGS THAT KNOCKOUT OF BPLF1 DELAYS AND REDUCES HUMAN B-CELL IMMORTALIZATION AND LYMPHOMA FORMATION IN HUMANIZED MICE. THE AIM OF THIS PROPOSAL IS TO DISCOVER AND CHARACTERIZE THE FIRST-IN-WORLD SMALL MOLECULE INHIBITORS OF BPLF1 DEUBIQUITINATING ACTIVITY. THE GOALS OF THIS PROPOSAL ARE TO 1) USE HIGH THROUGHPUT SCREENING TO IDENTIFY NOVEL CHEMOTYPES FOR A LEAD OPTIMIZATION EFFORT AND 2) PRODUCE FURTHER VALIDATION THAT SMALL MOLECULE INHIBITION OF BPLF1 DEUBIQUITINATING ACTIVITY IS A PROMISING AVENUE FOR TREATING DISEASES CAUSED BY EBV INFECTION. THIS WORK WILL LAY THE FOUNDATION FOR A CHEMICAL PROBE AND DRUG DISCOVERY EFFORT TO COMBAT EBV-ASSOCIATED DISEASE.

Obligated Amount:

453750.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Date:

2025-05-14

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

THE ROLE OF DNA POLYMERASE DELTA 4 IN LUNG CARCINOGENESIS INDUCED BY GENOTOXIC CARCINOGENS - ABSTRACT LUNG CANCER IS THE LEADING CAUSE OF CANCER-RELATED DEATH IN THE WORLD. EXPOSURES TO AIRBORNE CARCINOGENS CONTRIBUTE SIGNIFICANTLY TO LUNG CARCINOGENESIS. GENOTOXIC CARCINOGENS, WHICH CAN COME FROM ENVIRONMENTAL AND/OR OCCUPATIONAL SETTINGS, ARE THE MOST IMPORTANT CAUSES OF LUNG MALIGNANCY IN HUMANS. THESE INCLUDE HEXAVALENT CHROMIUM (CR(VI)), NICOTINE-DERIVED NITROSAMINE KETONE (NNK), BENZO(A)PYRENE (BAP), AND URETHANE. EXPOSURE TO THESE CARCINOGENS CAN LEAD TO FORMATION OF DNA ADDUCTS THAT INDUCE DNA DOUBLE-STRAND BREAKS. DNA DAMAGE IS A KEY EARLY EVENT AND THE DRIVING FORCE OF GENETIC ABNORMALITIES THAT LEAD TO MALIGNANT TRANSFORMATION OF NORMAL LUNG EPITHELIAL CELLS. IN HUMANS, THERE ARE TWO FORMS OF POLΔ: POLΔ4 AND POLΔ3. POLΔ4 IS A TETRAMER CONTAINING THE P12 SUBUNIT WHICH IS ABSENT IN YEAST. THE DEGRADATION OF P12 IN RESPONSE TO DNA DAMAGE LEADS TO THE CONVERSION OF POLΔ4 TO POLΔ3. THIS IS A NOVEL CELLULAR REGULATORY SYSTEM THAT ORCHESTRATES THE FORMATION OF POLΔ3 WHICH PLAYS A KEY ROLE IN DNA REPAIR AND REPLICATION. OUR RECENT WORK SHOWS THAT POLΔ4 IS THE ENZYME FORM THAT IS INVOLVED IN THE KEY STEP IN HOMOLOGY DIRECTED REPAIR (HDR) OF DSBS. LOSS OF POLΔ4 LEADS TO HDR DEFICIENCY AND IS A NOVEL POTENTIAL CONTRIBUTOR TO TUMORIGENESIS. OUR GOALS ARE DIRECTED TO THE UNEXPLORED ROLES OF POLΔ4 LOSS IN LUNG TUMORIGENESIS. OUR FIRST AIM IS TO CHARACTERIZE THE EFFECTS OF THE LUNG CARCINOGENS (CR(VI), BAP AND NNK ON P12 DEGRADATION IN LUNG EPITHELIAL CELL LINES AS WELL AS THE MECHANISMS INVOLVED IN THIS PROCESS. THESE STUDIES HAVE NOT BEEN DONE IN NON-NEOPLASTICALLY TRANSFORMED CELLS. WE WILL STUDY THE POTENTIAL OF CHRONIC EXPOSURE TO THE ABOVE-MENTIONED CARCINOGENS ON P12 DEGRADATION, AS WELL AS THEIR CAPACITY TO LEAD TO EPIGENETIC CHANGES THAT SUPPRESS P12 EXPRESSION AFTER CHRONIC EXPOSURE. OUR SECOND AIM IS TO TEST THE HYPOTHESIS THAT P12 DEPLETION FACILITATES NEOPLASTIC TRANSFORMATION OF LUNG EPITHELIAL CELLS. WE WILL EXAMINE WHETHER P12 DELETION PROMOTES NEOPLASTIC TRANSFORMATION OF LUNG EPITHELIAL CELLS INDUCED BY THESE CARCINOGENS. WE WILL ALSO INVESTIGATE WHETHER P12 DELETION ENHANCES THE ABILITY OF URETHANE TO INDUCE LUNG TUMORS TO PROVIDE AN IN VIVO READOUT OF THE EFFECTS OF P12 ON LUNG TUMORIGENESIS. AS DELETION OF P12 ELIMINATES THE POSSIBILITY OF FORMING THE POLΔ4 ENZYME, THE P12 KNOCKOUT CELL AND MOUSE MODELS ARE ABSENT OF POLΔ4. THESE MODELS THUS HAVE A UNIQUE AND DEFINED LOCUS IN THE CONVERGENT STEP OF D-LOOP EXTENSION, A CRUCIAL STEP IN HDR. THE P12 KNOCKOUT MOUSE MODEL PROVIDES A UNIQUE OPPORTUNITY TO EXAMINE THE ROLE OF P12 IN LUNG CARCINOGENESIS INDUCED BY GENOTOXIC CARCINOGENS IN VIVO IN A CLEAN BACKGROUND. THESE STUDIES WILL LEAD TO EVIDENCE FOR A ROLE OF POLΔ4 IN LUNG TUMORIGENESIS THAT ORIGINATES FROM A NOVEL ROUTE TO HR-DEFICIENCY AND HAVE THE POTENTIAL TO OPEN UP FURTHER AVENUES OF RESEARCH THAT COULD CONTRIBUTE TO FUTURE THERAPEUTIC APPROACHES IN LUNG CANCER.

Obligated Amount:

453698.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Date:

2025-05-05

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

PROTEINSIMPLE JESS SYSTEM FOR PROTEIN ANALYSIS AT NYMC - PROJECT SUMMARY THIS IS A REQUEST FOR JESS PROTEIN ANALYSIS SYSTEM (PROTEIN SIMPLE) TO BE INTEGRATED INTO THE NEW YORK MEDICAL COLLEGE (NYMC) FOR PROTEIN QUANTITATION AND CHARACTERIZATION. NYMC IS DEDICATED TO BUILDING BIOMEDICAL RESEARCH. A KEY PART OF NYMC STRATEGIC PLAN IS IMPROVING INVESTIGATOR-IDENTIFIED CRITICAL CORE RESEARCH FACILITIES. SURVEYS OF NYMC FUNDED INVESTIGATORS, INCLUDING THOSE FUNDED BY NIH AND THOSE FUNDED FROM OTHER SOURCES, CONSISTENTLY RANK A PROTEIN ANALYSIS SYSTEM THAT MAY QUANTITATIVE AND REPRODUCIBLE RESULTS AS THE MOST ESSENTIAL CORE PIECE OF EQUIPMENT FOR THEIR CURRENT AND FUTURE RESEARCH, ESPECIALLY IN THE ABSENCE OF A FUNCTIONAL PROTEOMICS CORE. THE PROPOSED PROTEINSIMPLE JESS SYSTEM INTEGRATED INTO THE COLLEGE HISTOLOGICAL LABORATORY AND IMAGING CORE WILL MEET A TREMENDOUS UNMET NEED FOR INVESTIGATORS FOR STATE-OF-THE ART AUTOMATED SIZE-BASED SEPARATION AND NANO-IMMUNOASSAY PLATFORM FOR THE DETECTION AND CHARACTERIZATION OF PROTEINS MOLECULAR WEIGHTS IN DENATURED PROTEIN FROM TISSUES, CELLS, AND EXTRACELLULAR PARTICLES (EXTRACELLULAR VESICLES AND EXTRACELLULAR CONDENSATES). THE RESEARCH OF MANY OF THE MAJOR AND MINOR USERS AT NYMC INVOLVES ANALYSIS OF GENE EXPRESSION AT THE PROTEIN LEVEL AND THE ENHANCED SIGNAL TO NOISE RATIO PROVIDED BY THE PROTEINSIMPLE JESS SYSTEM IS ESSENTIAL. CURRENTLY THERE IS NOT A FUNCTIONAL PROTEOMICS CORE AT NYMC. THE PROPOSAL INCLUDES 4 NIH-FUNDED MAJOR USERS FROM VARIOUS DEPARTMENTS AND DISCIPLINES AT NYMC. NIH FUNDED USERS COMPRISE 100% OF THE ESTIMATED ACCESSIBLE USER TIME (AUT) FOR THE INSTRUMENT. THE OTHER USERS COMPRISE ADDITIONAL INVESTIGATORS WITH CRITICAL NEED FOR QUANTITATIVE AND REPRODUCIBLE RESULTS. THERE IS NO FUNCTIONAL PROTEIN ANALYSIS CORE OR EQUIPMENT AT NYMC. ALL INVESTIGATORS DEPEND ON TRADITIONAL WESTERN BLOTTING THAT IS PLAGUED BY POOR REPRODUCIBILITY, LACK OF ACCURATE QUANTITATION, EXTENSIVE TIME TO RESULT AND RELIABILITY ISSUES. ALL MAJOR/MINOR USERS HAVE AGREED THAT THE PROTEINSIMPLE JESS SYSTEM WILL BEST FIT THE CURRENT/FUTURE NEEDS OF INVESTIGATORS TO PROVIDE MORE QUANTITATIVE AND REPRODUCIBLE RESULTS, THUS, MEETING ESTABLISHED GUIDELINES ON NIH’S REPRODUCIBILITY AND RIGOR. IN ADDITION TO THE AUTOMATION, SENSITIVITY, AND THROUGHPUT ADVANTAGES OF THE PROTEINSIMPLE JESS SYSTEM, THE SYSTEM CREATES ELECTRONIC DATA FILES THAT ARE IMPERVIOUS TO MANIPULATION, AS IT CONTAINS THE RAW AND ANALYZED DATA, WHICH CAN EASILY BE UPLOADED TO A DATA REPOSITORY WHEN IT COMES TIME TO PUBLISH. IN SUMMARY, THE PROTEINSIMPLE JESS SYSTEM PROMOTES DATA REPRODUCIBILITY BECAUSE IT PRECISELY CONTROLS SAMPLE LOADING, ANTIBODY ADDITIONS, INCUBATIONS, AND ALL WASHES, THEREBY ELIMINATING THE INCONSISTENCIES AND USER-DEPENDENT VARIABILITY THAT MAY BE INTRODUCED DURING TRADITIONAL WESTERN BLOTTING, CULMINATING IN INTRA-ASSAY COEFFICIENTS OF VARIABILITY (CVS) <15%.

Obligated Amount:

97363.70

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Date:

2025-04-10

Link:

View on USAspending

Awarding Agency Name:

Department of Health and Human Services

Transaction Description:

TREATMENT PLANNING SYSTEM FOR ELECTRON FLASH RADIATION THERAPY - ABSTRACT ULTRA-HIGH DOSE RATE (UHDR) RADIATION DELIVERY, TERMED FLASH RADIOTHERAPY (FLASH-RT), HAS THE POTENTIAL TO REDUCE NORMAL TISSUE DAMAGE, WITH SIGNIFICANT CLINICAL CANCER TREATMENT RAMIFICATIONS. CURRENT EVIDENCE SUGGESTS THAT FLASH-RT REDUCES FUNCTIONAL DAMAGE TO NORMAL BRAIN, COLON, LUNG, AND SKIN, AT THE SAME DOSE VALUES. ALTHOUGH CONTROVERSIAL, SOME STUDIES SHOW THIS REDUCTION IN TISSUE DAMAGE AS GREAT AS 40%, DESPITE TISSUE TYPE ALPHA/BETA RATIO AND TOTAL DOSE REMAIN SIGNIFICANT UNKNOWN FACTORS. MOST SURPRISINGLY TUMOR TISSUE APPEARS UNAFFECTED BY FLASH RADIATION SPARING, SUGGESTING THAT THE THERAPEUTIC RATIO ACHIEVED THROUGH FLASH-RT IS HIGHER THAN CONVENTIONAL RT. THE POTENTIAL TO ACHIEVE HIGHER THERAPEUTIC RATIOS MAKE FLASH-RT VERY ATTRACTIVE FOR FUTURE HUMAN USE TO ADDRESS RADIORESISTANT TUMORS THAT WOULD OTHERWISE RESULT IN EXCESSIVE RADIOTOXICITY DURING CONVENTIONAL TREATMENT. DESPITE CLINICAL TRANSLATION OF FLASH-RT TO LARGE ANIMAL AND HUMAN STUDIES BEING URGENTLY WARRANTED, THE MAJORITY OF THE PRECLINICAL WORK FOR FLASH-RT REMAINS IN SMALL ANIMALS, WHERE CONCERNS REGARDING DOSE AND DOSE RATE INHOMOGENEITIES CANNOT BE ADEQUATELY ASSESSED. A MAJOR BARRIER TOWARDS TRANSLATIONAL FLASH-RT IS THAT OPTIMIZATION OF TREATMENT PLANS FOR LARGE ANIMALS AND HUMANS WITH LARGER/DEEPER TISSUES AND COMPLICATED GEOMETRIES REMAINS CHALLENGING. IN ORDER TO DEMONSTRATE THE HYPOTHESIZED SUPERIORITY OF FLASH-RT, IT IS ESSENTIAL TO CONDUCT THE STUDIES FLASH-RT STUDIES UNDER CONTROLLED CONDITIONS AND IN CLINICALLY REALISTIC WORKFLOWS. THIS BEGINS WITH A TREATMENT PLANNING SYSTEM {TPS) CAPABLE OF GENERATING AND DELIVERING COMPARABLE PLANS FOR FLASH/CONV-RT WITHIN A MINIMALLY MODIFIED CLINICAL SETTING. IN THE CURRENT PROPOSAL, WE ARE COMMITTED TO DEVELOPING SUCH A TPS FOR THE FIRST TIME AND MAKING OUR SOFTWARE AVAILABLE TO THE SCIENTIFIC COMMUNITY. WE WILL ACHIEVE THIS BY FIRST GENERATING BEAM MODELS FOR FLASH-CAPABLE LINACS. THESE BEAM MODELS WILL THEN BE USED TO IMPLEMENT ADVANCED PLANNING AND DELIVERY TECHNOLOGY UTILIZING PASSIVE INTENSITY MODULATION. NEXT, WE WILL DEVELOP TUMOR CONTROL PROBABILITY AND NORMAL TISSUE COMPLICATION PROBABILITY MODELS DEPLOYABLE ON THE TPS. LASTLY, OUR WORK WILL CULMINATE IN DEMONSTRATING SUCCESSFUL DELIVERIES OF OPTIMIZED PLANS WITH COMPREHENSIVE CHARACTERIZATION OF PLAN DELIVERY USING QUALITY ASSURANCE SYSTEMS UNIQUELY AVAILABLE AT DARTMOUTH. DUE TO THE URGENCY TO TRANSFER THIS PARADIGM-SHIFTING THERAPY, HIGH-RISK OF THE FIRST INITIATIVE, THE EXPLORATORY, AND DEVELOPMENTAL NATURE OF THE PROPOSAL, THE R21 GRANT MECHANISM IS LEVERAGED AND JUSTIFIED. THE SUCCESSFUL COMPLETION OF THE PROPOSED WORK WILL ADVANCE THE STATE-OF-THE-ART IN FLASH-RT BY BRIDGING THE EXTENSIVE GAP BETWEEN THE BASIC SCIENCE OF FLASH AND THE CLINICAL NEEDS OF FLASH FOR TRANSLATION TO HUMAN TRIALS. THE TEAM HAS LEADING EXPERTISE IN RADIATION PHYSICS, INFORMATICS, AND RADIATION ONCOLOGY, AND ARE SUPPORTED BY EXISTING FLASH-CAPABLE LINACS, TPS PROTOTYPES, UNIQUE UHDR DOSIMETRY TECHNOLOGIES INVENTED AT DARTMOUTH, CANINE PILOT TRIALS, FUTURE HUMAN TRIALS IN PLANNING AND LEADING INDUSTRIAL PARTNERS. TAKEN TOGETHER, THE TEAM IS IDEALLY POISED TO CONDUCT THE PROPOSED WORK OF EXPLORATORY AND DEVELOPMENTAL NATURE.

Obligated Amount:

218796.00

Face Value Of Loan:

0.00

Total Face Value Of Loan:

0.00

Trademarks Section

Serial Number:

85740878

Mark:

IBIO-NY

Status:

Abandoned because the applicant failed to respond or filed a late response to an Office action. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.

Mark Type:

Service Mark

Application Filing Date:

2012-09-28

Mark Drawing Type:

5 - AN ILLUSTRATION DRAWING WITH WORD(S)/LETTER(S)/NUMBER(S) IN STYLIZED FORM

Mark Literal Elements:

IBIO-NY

USPTO Link:

View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:

Promoting collaboration within the scientific, research and medical communities to achieve advances in the field of healthcare

First Use:

2012-05-01

International Classes:

035 - Primary Class

Class Status:

ACTIVE

Serial Number:

74668124

Mark:

CHILDREN'S CANCER RESEARCH FUND OF NEW YORK MEDICAL COLLEGE

Status:

Abandoned after an inter partes decision by the Trademark Trial and Appeal Board. For further information, see TTABVUE on the Trademark Trial and Appeal Board web page.

Mark Type:

Trademark, Service Mark

Application Filing Date:

1995-05-01

Mark Drawing Type:

3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S) /NUMBER(S)

Mark Literal Elements:

CHILDREN'S CANCER RESEARCH FUND OF NEW YORK MEDICAL COLLEGE

USPTO Link:

View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:

T-shirts, golf shirts, sweatshirts, caps and jackets

First Use:

1994-04-01

International Classes:

025 - Primary Class

Class Status:

ACTIVE

For:

charitable fund raising services to support cancer research

First Use:

1993-04-19

International Classes:

036 - Primary Class

Class Status:

ACTIVE

OSHA's Inspections within Industry

13-1099420

In Care Of Name:

% ADAM HAMMERMAN

Classification:

Educational Organization, Local Association of Employees, Horticultural Organization, Business League, Voluntary Employees' Beneficiary Association (Govt. Emps.), Mutual Ditch or Irrigation Co., Cemetery Company, Other Mutual Corp. or Assoc.

Ruling Date:

1940-08

Deductibility:

Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Court Cases

Court Case Summary

Filing Date:

2009-03-27

Status:

Terminated

Nature Of Judgment:

Missing

Jury Demand:

Plaintiff demands jury

Nature Of Suit:

Civil Rights Employment

Parties

Party Name:

BALAZY

Party Role:

Plaintiff

Party Name:

NEW YORK MEDICAL COLLEGE

Party Role:

Defendant

Court Case Summary

Filing Date:

2007-04-02

Status:

Terminated

Nature Of Judgment:

Missing

Jury Demand:

Missing

Nature Of Suit:

Other Labor Litigation

Parties

Party Name:

MUCCI

Party Role:

Plaintiff

Party Name:

NEW YORK MEDICAL COLLEGE

Party Role:

Defendant

Name:	NEW YORK MEDICAL COLLEGE
Jurisdiction:	New York
Legal type:	DOMESTIC NOT-FOR-PROFIT CORPORATION
Status:	Active
Date of registration:	16 Jun 1939 (86 years ago)
Entity Number:	40621
ZIP code:	10595
County:	Westchester
Place of Formation:	New York
Address:	ADMINISTRATION BUILDING, SUNSHINE COTTAGE, VALHALLA, NY, United States, 10595

Is this your business?

Company Details

Agent

DOS Process Agent

Unique Entity ID

Business Information

Commercial and government entity program

Contact Information

Immediate Level Owner

National Provider Identifier

Authorized Person:

Taxonomy:

Contacts:

Form 5500 Series

History

Filings

USAspending Awards / Contracts

USAspending Awards / Financial Assistance

Trademarks Section

Goods And Services

Goods And Services

OSHA's Inspections within Industry

Inspection Summary

Inspection Summary

Inspection Summary

Inspection Summary

Inspection Summary

Tax Exempt

Court Cases

Court Case Summary

Parties

Court Case Summary

Parties

Reviews Leave a review

NEW YORK MEDICAL COLLEGE

Is this your business?

Company Details

Agent

DOS Process Agent

Unique Entity ID

Business Information

Commercial and government entity program

Contact Information

Immediate Level Owner

National Provider Identifier

Authorized Person:

Taxonomy:

Contacts:

Form 5500 Series

History

Filings

USAspending Awards / Contracts

USAspending Awards / Financial Assistance

Trademarks Section

Goods And Services

Goods And Services

OSHA's Inspections within Industry

Inspection Summary

Inspection Summary

Inspection Summary

Inspection Summary

Inspection Summary

Tax Exempt

Court Cases

Court Case Summary

Parties

Court Case Summary

Parties

Reviews Leave a review

Related by officers

Related by address